SCHEMBL3834072

SCHEMBL3834072

COCCNC(=O)[C@@H]1CCCN1C

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.48
HPGD P15428 2/20 0.48
MAPT P10636 1/20 0.47
ATM Q13315 1/20 0.46
TDP1 Q9NUW8 2/20 0.45
ALDH1A1 P00352 2/20 0.45
CYP3A4 P08684 2/20 0.44
CYP2D6 P10635 1/20 0.44
POLB P06746 1/20 0.42
TSHR P16473 1/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
CYP2C19 P33261 1/20 0.41
LMNA P02545 1/20 0.41
ALOX15 P16050 1/20 0.41
CNR2 P34972 1/20 0.41
NPSR1 Q6W5P4 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3830058 0.98 TDP1 (0.48) KDM4EHPGDMAPTATMTDP1
SCHEMBL20061831 0.85 TSHR (0.47) KDM4EHPGDMAPTALDH1A1CYP3A4
SCHEMBL12733425 0.84 TSHR (0.52) KDM4EALDH1A1CYP3A4CYP2D6POLB
SCHEMBL13102177 0.84 MAPT (0.48) KDM4EHPGDMAPTATMTDP1
SCHEMBL4577535 0.83 CYP3A4 (0.47) CYP3A4CYP2D6POLBTSHRLMNA
SCHEMBL5737180 0.83 CYP3A4 (0.47) CYP3A4CYP2D6POLBTSHRLMNA
SCHEMBL12733389 0.83 NPSR1 (0.48) KDM4EHPGDTDP1ALDH1A1CYP3A4
SCHEMBL4579409 0.83 CYP3A4 (0.47) CYP3A4CYP2D6POLBTSHRALOX15
SCHEMBL4577528 0.83 CYP3A4 (0.47) CYP3A4CYP2D6POLBTSHRALOX15
SCHEMBL26343602 0.83 NPSR1 (0.48) KDM4EHPGDTDP1ALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8440626-B2 Antineoplastic peptides ABBOTT GMBH & CO. KG (DE) 2013-05-14 US disclosed
US-8440626-B2 Antineoplastic peptides ABBOTT GMBH & CO. KG (DE) 2013-05-14 US disclosed
US-20110098235-A1 ANTINEOPLASTIC PEPTIDES ABBOTT GMBH & CO. KG (DE) 2011-04-28 US disclosed
US-7807779-B2 Antineoplastic peptides ABBOTT GMBH & CO. KG (DE) 2010-10-05 US disclosed
US-7807779-B2 Antineoplastic peptides ABBOTT GMBH & CO. KG (DE) 2010-10-05 US disclosed
US-20090312310-A1 Imidazothiazole derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-12-17 US disclosed
EP-2103619-A1 IMIDAZOTHIAZOLE DERIVATIVES Daiichi Sankyo Company, Limited (JP) 2009-09-23 EP disclosed
US-20080234205-A1 Antineoplastic peptides ABBOTT GMBH & CO. KG (DE) 2008-09-25 US disclosed
US-20080234205-A1 Antineoplastic peptides ABBOTT GMBH & CO. KG (DE) 2008-09-25 US disclosed
US-7368528-B2 Antineoplastic peptides ABBOTT GMBH & CO. KG (DE) 2008-05-06 US disclosed
US-7368528-B2 Antineoplastic peptides ABBOTT GMBH & CO. KG (DE) 2008-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312310-A1 Imidazothiazole derivatives TP53, MDM2, TP53BP1 KDM4E 1716/4885HPGD 3042/4885MAPT 3039/4885
US-20080234205-A1 Antineoplastic peptides BCL2A1, ETF1, BAK1 KDM4E 2238/4885HPGD 2498/4885MAPT 4864/4885
US-20110098235-A1 ANTINEOPLASTIC PEPTIDES BCL2A1, CSTB, BAK1 KDM4E 3028/4885HPGD 2705/4885MAPT 4877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.